Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $61,376.84 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Preethi Sundaram sold 2,324 shares of the company’s stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider now directly owns 42,681 shares of the company’s stock, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Preethi Sundaram also recently made the following trade(s):

• On Wednesday, June 11th, Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $26.42, for a total value of $42,272.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $24.29 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.58. The firm has a 50-day simple moving average of $23.81 and a 200-day simple moving average of $22.85. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of 20.58, a price-to-earnings-growth ratio of 3.31 and a beta of 0.72.

Wall Street Analyst Weigh In

Several brokerages have commented on CPRX. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird increased their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Stephens reaffirmed an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. Finally, Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Six research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.83.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the 4th quarter valued at $29,000. Sound Income Strategies LLC purchased a new position in Catalyst Pharmaceuticals during the 1st quarter worth $64,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 579 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.